BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 26186073)

  • 1. Chemotherapy as Adjuvant Treatment for Intermediate-High Risk Early-Stage Endometrial Cancer: A Pilot Study.
    Aloisi A; Plotti F; Scaletta G; Capriglione S; Laraud F; Miranda A; Montera R; De Cicco Nardone C; Terranova C; Angioli R
    Int J Gynecol Cancer; 2015 Oct; 25(8):1418-23. PubMed ID: 26186073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent cisplatin/radiation followed by adjuvant cisplatin/paclitaxel in treatment of patients with stage IB grade 3, IC and IIA endometrial carcinoma.
    Foad I; Sharawy I; Mostafa E; Margergis M; Hussein T
    J Egypt Natl Canc Inst; 2007 Jun; 19(2):163-9. PubMed ID: 19034346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant chemotherapy as treatment of high-risk stage I and II endometrial cancer.
    Aoki Y; Watanabe M; Amikura T; Obata H; Sekine M; Yahata T; Fujita K; Tanaka K
    Gynecol Oncol; 2004 Aug; 94(2):333-9. PubMed ID: 15297170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancer.
    Milgrom SA; Kollmeier MA; Abu-Rustum NR; Tew WP; Sonoda Y; Barakat RR; Alektiar KM
    Gynecol Oncol; 2013 Sep; 130(3):436-40. PubMed ID: 23800696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined chemotherapy regimen of carboplatin and paclitaxel as adjuvant treatment for papillary serous and clear cell endometrial cancer.
    Shechter-Maor G; Bruchim I; Ben-Harim Z; Altaras M; Fishman A
    Int J Gynecol Cancer; 2009 May; 19(4):662-4. PubMed ID: 19509567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The importance of adjuvant chemotherapy and pelvic radiotherapy in high-risk early stage endometrial carcinoma.
    Jutzi L; Hoskins P; Lim P; Aquino-Parsons C; Tinker A; Kwon JS
    Gynecol Oncol; 2013 Dec; 131(3):581-5. PubMed ID: 24055614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and prognostic implications of administering adjuvant chemotherapy to patients with endometrial cancer that is confined to the uterus.
    Kodama J; Seki N; Ojima Y; Nakamura K; Hongo A; Hiramatsu Y
    Eur J Obstet Gynecol Reprod Biol; 2007 Mar; 131(1):76-80. PubMed ID: 16459012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer.
    Lupe K; D'Souza DP; Kwon JS; Radwan JS; Harle IA; Hammond JA; Carey MS
    Gynecol Oncol; 2009 Jul; 114(1):94-8. PubMed ID: 19406459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics.
    Young MR; Higgins SA; Ratner E; Yu JB; Mani S; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Damast S
    Int J Gynecol Cancer; 2015 Mar; 25(3):431-9. PubMed ID: 25621409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Outcome of Patients With High-Risk Endometrial Carcinoma After Treatment With Chemotherapy Only.
    Smogeli E; Cvancarova M; Wang Y; Davidson B; Kristensen G; Lindemann K
    Int J Gynecol Cancer; 2018 Nov; 28(9):1789-1795. PubMed ID: 30365455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five-year outcomes of adjuvant carboplatin/paclitaxel chemotherapy and intravaginal radiation for stage I-II papillary serous endometrial cancer.
    Kiess AP; Damast S; Makker V; Kollmeier MA; Gardner GJ; Aghajanian C; Abu-Rustum NR; Barakat RR; Alektiar KM
    Gynecol Oncol; 2012 Nov; 127(2):321-5. PubMed ID: 22850412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequential versus "sandwich" sequencing of adjuvant chemoradiation for the treatment of stage III uterine endometrioid adenocarcinoma.
    Lu SM; Chang-Halpenny C; Hwang-Graziano J
    Gynecol Oncol; 2015 Apr; 137(1):28-33. PubMed ID: 25666606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Applicability of the concept of "platinum sensitivity" to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study.
    Nagao S; Nishio S; Michimae H; Tanabe H; Okada S; Otsuki T; Tanioka M; Fujiwara K; Suzuki M; Kigawa J
    Gynecol Oncol; 2013 Dec; 131(3):567-73. PubMed ID: 24076450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practice pattern for postoperative management of endometrial cancer in Japan: a survey of the Japanese Gynecologic Oncology Group.
    Watanabe Y; Kitagawa R; Aoki D; Takeuchi S; Sagae S; Sakuragi N; Yaegashi N;
    Gynecol Oncol; 2009 Dec; 115(3):456-9. PubMed ID: 19765806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant docetaxel and carboplatin chemotherapy administered alone or with radiotherapy in a "sandwich" protocol in patients with advanced endometrial cancer: a single-institution experience.
    Lan C; Huang X; Cao X; Huang H; Feng Y; Huang Y; Liu J
    Expert Opin Pharmacother; 2013 Apr; 14(5):535-42. PubMed ID: 23480059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Feasibility Study of Adjuvant Chemotherapy Using Taxane Plus Carboplatin for High-Risk Patients With Uterine Cervical Non-Squamous Cell Carcinoma After Radical Hysterectomy.
    Sato S; Shimada M; Ohta T; Kojimahara T; Tokunaga H; Takano T; Yamaguchi S; Tanabe H; Nishio S; Kigawa J
    Int J Gynecol Cancer; 2016 Mar; 26(3):561-7. PubMed ID: 26825829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience.
    Kim HS; Kim JW; Wu HG; Chung HH; Park NH; Song YS; Kang SB; Lee HP
    J Obstet Gynaecol Res; 2010 Jun; 36(3):598-604. PubMed ID: 20598043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study.
    Susumu N; Sagae S; Udagawa Y; Niwa K; Kuramoto H; Satoh S; Kudo R;
    Gynecol Oncol; 2008 Jan; 108(1):226-33. PubMed ID: 17996926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.
    Duska LR; Berkowitz R; Matulonis U; Muto M; Goodman A; McIntyre JF; Klein A; Atkinson T; Seiden MV; Campos S
    Gynecol Oncol; 2005 Jan; 96(1):198-203. PubMed ID: 15589601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preliminary analysis of RTOG 9708: Adjuvant postoperative radiotherapy combined with cisplatin/paclitaxel chemotherapy after surgery for patients with high-risk endometrial cancer.
    Greven K; Winter K; Underhill K; Fontenesci J; Cooper J; Burke T;
    Int J Radiat Oncol Biol Phys; 2004 May; 59(1):168-73. PubMed ID: 15093913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.